Literature DB >> 7940165

Blood conservation in coronary artery surgery.

G Paone1, T Spencer, N A Silverman.   

Abstract

BACKGROUND: Most patients undergoing coronary artery bypass surgery receive homologous blood transfusions despite the availability of multiple pharmacologic and blood salvage conservation strategies.
METHODS: The efficacy of defining strict transfusion criteria as the sole blood conservation strategy was adjudicated prospectively by comparing homologous blood product usage in 314 consecutive patients undergoing isolated primary coronary artery bypass surgery (group 2) with a retrospective group of 947 consecutive patients undergoing the same procedure but transfused without protocol (group 1).
RESULTS: The incidence of red cell transfusion and plasma transfusion decreased from 40.5% to 25.8% and 23.8% to 13.4% in groups 1 and 2, respectively (p < 0.001). The percentage of patients receiving no homologous blood products increased from 47.6% in group 1 to 68.5% in group 2 (p < 0.001). Decreasing body weight and preoperative hematocrit were found to be highly significant predictors of the need for red blood cell transfusion (p < 0.001). Significant postoperative determinants included intensive care unit and hospital length of stay and reoperation for bleeding (p < 0.001 each).
CONCLUSIONS: Because major determinant of homologous blood transfusion during coronary bypass surgery is the predictable and unavoidable dilution of a small red cell mass that occurs when instituting cardiopulmonary bypass, adherence to defined transfusion criteria alone is a simple, safe, and effective strategy for decreasing blood product utilization.

Entities:  

Mesh:

Year:  1994        PMID: 7940165

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  3 in total

1.  Safety and efficacy of blood donation prior to elective cardiac surgery in anemic patients.

Authors:  H Kiyama; N Ohshima; T Imazeki
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2000-02

2.  Blood component therapy: Which, when and how much.

Authors:  Rajesh Chand Arya; Gs Wander; Pankaj Gupta
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2011-04

3.  Debate: transfusing to normal haemoglobin levels will not improve outcome.

Authors:  G Alvarez; P C Hébert; S Szick
Journal:  Crit Care       Date:  2001-03-08       Impact factor: 9.097

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.